Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
August 19, Saturday 2017 6:35 PM       

       HEADLINES: Sreenath's family submits complaint to CM                                              Probe needed against Thomas Chandy: A K Antony                                              Malappuram collector orders to remove check-dam constructed by P V Anwar MLA                                              Yet another ‘Blue Whale’ death in Kerala? Mother talks about her dead son                                              Banned currency worth Rs. 10 crore ceased from Kayamkulam                                              Solution to Kashmir, terrorism, before 2022: Rajnath                                              Yogi takes dig at Rahul, says Gorakhpur isn’t 'picnic spot'                                              RBI to issue new fluorescent blue Rs 50 notes                                              14 dead in twin attacks as Spanish police launch manhunt                                              Indonesia begins countdown to 2018 Asian Games                                              Some felt Kumble was strict but not me, says Wriddhiman Saha                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Rooter includes Kabbadi, F1 under one roof  
Orbiting supermassive black holes discovered for first time  
Theweightmonitor.com launches mobile app for easier access to one-stop weight management platform  
New drug to treat blood cancer developed  
Threat of asteroid impact looming over Earth: experts  
Hottest known planet in universe discovered  
Wireless, battery-less pacemaker developed  
'Manned missions to Moon, Mars may face medical emergencies'  
Ransomware threat: Centre activates mechanism to prevent ‘Wannacry’ cyber attack  
2 lakh hit by 'unprecedented' cyberhack in 150 nations:Europol  
foodpanda revamps mobile app; provides more options  
ixigo launches trains app for Apple iOS users  
Virtual humans may help doctors learn empathy: study  
Gamers, here are five games to watch out for  
Yahoo India homepage gets brand new look  
Spacecraft flies between Saturn and rings in historic 1st  
Google targets 'fake news,' offensive search suggestions  
Offensive WhatsApp posts can land group admin in jail  
Facebook for 'everyone' and not just high end: Zuckerberg  
Google Earth re-invented for new era  
NASA images show how India looks from space at night  
Signs of life detected below world's deepest point  
'iPhones assembly in Bengaluru by Apple in less than a month'  
Five astronauts assigned to future ISS mission: NASA  
Trump plans to send humans to Mars  
 
Do you think Pulsar Suni's Madam is a spoof?
yes
 
no
 
don't know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy